Tracers / [177Lu]Lu-rhPSMA-7
[177Lu]Lu-rhPSMA-7
Also written as [Lu-177]Lu-rhPSMA-7; rhPSMA-7.3
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- PSMA-targeted radiohybrid (rh) ligand
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 35086894
- Clinical application
- Endoradiotherapy (radioligand therapy) of prostate cancer PMID 35086894
- Theranostic pair
- <a href="/tracers/f18-rhpsma7/">f18-rhpsma7</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | >95% | rhPSMA-7.3 | 36145382 2022 Pharmaceuticals (Basel) |
| Manual synthesis | — | — | — | >95% | rhPSMA-7.3 precursor | 35086894 2022 J Nucl Med 177Lu labeling of PSMA ligands according to standard manual procedures resulted in a radiochemical purity of more than 95% |
Need this precursor?We can point you to suppliers for [177Lu]Lu-rhPSMA-7, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - F-18.